Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.36 |
| ▸ | SCN3A | Q9NY46 | 4/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | SCN4A | P35499 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29145446 | 0.86 | NPC1 (0.36) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL23306592 | 0.82 | PDK1 (0.38) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL28560728 | 0.82 | PDK1 (0.38) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL29145449 | 0.73 | DPP4 (0.41) | NPC1RAB9ASMN1; SMN2TP53MAPT | |
| SCHEMBL29145421 | 0.72 | SCN4A (0.48) | SCN3ASCN9ASCN5ASCN4A | |
| SCHEMBL29145448 | 0.71 | SCN4A (0.49) | SCN3ASCN9ASCN5ASCN4A | |
| SCHEMBL15738520 | 0.71 | SCN4A (0.49) | SCN3ASCN9ASCN5ASCN4A | |
| SCHEMBL29145459 | 0.71 | NPC1 (0.35) | NPC1RAB9ASMN1; SMN2TP53MAPT | |
| SCHEMBL28549495 | 0.69 | DPP4 (0.45) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL28549493 | 0.69 | DPP4 (0.45) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117470-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2023-04-20 | — | — | US | disclosed |
| WO-2021087181-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117470-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS | TLR1, TLR3, TLR9 | NPC1 3133/4885RAB9A 943/4885SMN1; SMN2 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.